Phase 3 Trial to Compare CagriSema Delivery Devices for Weight Management

The global prevalence of obesity and overweight continues to rise, posing significant public health challenges and increasing the risk of numerous comorbidities like type 2 diabetes and cardiovascular disease. Combination therapies, such as CagriSema (a blend of semaglutide and cagrilintide), have shown promise in achieving substantial weight loss. However, ensuring consistent drug delivery and patient experience across different administration devices is crucial for widespread clinical adoption. This study specifically addresses the comparability of two different device presentations for injectable CagriSema.

As this study is not yet recruiting, specific results are unavailable. However, the trial is meticulously designed to rigorously compare the efficacy and safety profiles of the two different CagriSema presentations. Researchers will measure key endpoints such as percentage body weight change from baseline and the incidence of adverse events, aiming to demonstrate non-inferiority or equivalence between the two device presentations. The primary objective is to demonstrate the comparability of CagriSema administered via device 1 versus device 2, ensuring consistent therapeutic outcomes for weight reduction and safety across delivery methods. The study will also assess secondary endpoints like changes in body mass index (BMI), waist circumference, and other metabolic parameters, comparing both active treatment arms against placebo to quantify the treatment effect and confirm the overall benefit of CagriSema.